 After initial clinical trials against breast and renal-cell cancer were performed with this compound, the search for improved derivatives started.Particularly, lipophilic titanocene dichloride derivatives derived from fulvenes were synthesised in structural diversity and this led to the development of bis[("p"-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride, which became better known in the literature under its trivial name of Titanocene Y.

Titanocene Y is a cytotoxic apoptosis-inducing and anti-angiogenic drug candidate targeting renal-cell cancer and other solid tumors.The compound is transported via serum albumin selectively into cancer cells and targets their DNA by coordinating strongly to phosphate groups.